Drug Profile
Bulevirtide - MYR Pharma
Alternative Names: HEPCLUDEX; 915207G; Hepcludex; MyrB; Myrcludex-B; Myrcludex-B-MYR Pharma; Myrcludex™Latest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator INSERM; University of Heidelberg
- Developer Hepatera; MYR Pharma
- Class Antihyperlipidaemics; Antivirals; Hepatoprotectants; Lipopeptides
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Hepatitis D
- Phase II Hepatitis B
- No development reported Dyslipidaemias; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
Most Recent Events
- 10 Nov 2023 Efficacy data from a phase III trial in Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Efficacy and adverse events data from a phase II trial in Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Pooled efficacy data from phase II MYR204, MYR203 and phase III MYR301 trial in Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)